The Effect of Radiotherapy on the Concentration of Plasma Lipids in Elderly Prostate Cancer Patients

Edyta Wolny-Rokicka1,2, Andrzej Tukiendorf3, Jerzy Wydmański4, Katarzyna Brzeziakiewicz-Janus5, and Agnieszka Zembroń-Łacny1

Abstract
Lipids play an important role in processes such as the formation of membrane cells or in steroidogenesis, where androgens which stimulate the proliferation of prostate cancer (PCa) cells are produced. Previous studies presented links between cholesterol (CHOL) and PCa and concluded that cholesterol homeostasis changes in PCa patients during treatment and with age. This study further examines the correlation between the lipid profile, the treatment used, and the subjects’ age. Ninety-one subjects (Group 1: >69 years; Group 2: ≤69) histopathologically diagnosed with PCa were tested. Total CHOL, triglycerides (TG), high-density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL) were assessed from blood taken before the entire course of radiotherapy (RT) and in 3-month intervals after the treatment was completed, for up to 4 years (range: palliative and radical). In all the subjects, the CHOL decreased over time after RT \((p = .0445)\) with a simultaneous increase of prostate specific antigen (PSA) concentration \((p = .0366)\). A faster decrease of HDL was observed with a higher concentration of PSA \((p = .0053)\) and Gleason score \((p = .0304)\). In all the subjects, the HDL decreased after RT \((p = .0159)\) but in the older palliative group the HDL decrease progressed more slowly \((p = .0141)\). It could be stated, that after radical therapy TG levels tended to be consistently higher among younger men relative to the elderly \((p = .0151)\). But it was observed that RT treatment could lead to a decrease in the lipid serum concentration.

Keywords
elderly patients, cholesterol, prostate cancer, radiotherapy, triglycerides

Received October 21, 2018; revised March 30, 2019; accepted April 1, 2019

Lipids are organic compounds which may be divided into classes of biomolecules which ensure the proper metabolism and functioning of the organism. The major groups of lipoproteins in order of size are: chylomicrons, very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL). They enable the transport of multiple different fat molecules, including cholesterol (CHOL). Any malfunctioning of the anabolic or catabolic processes of lipoproteins may lead to the development of pathological processes in cells. The disorders in lipid and lipoprotein metabolism can be a result of the metabolic syndrome—overweight and obesity—which can be associated with a higher risk of cancer and can have an impact on the prognosis in cancer patients (Hashmi et al., 2015; Huang & Freter, 2015; Riedel, Abel, Swanevelder, & Gelderblom, 2015). A lot of previous research (Jowett, 1931; White, 1909; Yasuda & Bloor, 1932) noticed that CHOL accumulates in malignant tissues. CHOL is the precursor in steroidogenesis (Murai, 2015) in which androgens are produced, which in

1Department of Radiotherapy, Multispecialty Hospital in Gorzow Wielkopolski, Poland
2Faculty of Medicine and Health Sciences, University of Zielona Gora, Poland
3Social Medicine Department, Medical University in Wroclaw, Poland
4Department of Radiotherapy, Center of Oncology—Maria Sklodowska-Curie Memorial Institute, Branch in Gliwice, Poland
5Department of Hematology, University of Zielona Gora, Multispecialty Hospital in Gorzow Wielkopolski, Poland

Corresponding Author:
Edyta Wolny-Rokicka, Faculty of Medicine and Health Sciences, University of Zielona Gora, Zielona Gora, ul Zyty 28, 65-046 Zielona Gora, Poland.
Email: edyta.wolny@gmail.com
turn stimulate the proliferation of prostate cancer (PCa) cells. Other authors point to the importance of factors such as a healthy endothelium and a very strong antioxidative system in cancer progression. LDL protects the endothelium against oxidation and oxidatively modified LDL is an atherogenic risk factor. LDL is also proven to downregulate lysyl oxidase (LOX), which is a kind of protein crucial in the cancer invasion. LOX bonds with pseudopods of cancer cells and allows them to pierce the basement membrane of vessels and thus contributes to the invasion and migration of cancer cells (Rodriguez, Raposo, Martínez-González, Casani, & Badimon, 2002). If this LOX is downregulated, then the cancer cells cannot penetrate through the blood vessel and hence intravasation cannot take place. In the epidemiological studies (Anum & Adera, 2004), CHOL and LDL are reported to be significant risk factors in cardiovascular diseases, but with older age it changes and above the age of 70 these parameters are not risk factors any more. For men aged 80 years and above, the total CHOL identified an inverse relationship to mortality, that is, the subjects with low concentration levels of CHOL have a higher probability of death than subjects with a high concentration level of CHOL (diseases such as: cancer, infectious diseases, etc.). The objective of this study was to investigate whether there is a similar connection between lipid profiles and age in PCa patients. Hence, in order to evaluate the changes of plasma lipid profiles and the clinical significance of these, the two groups of PCa patients were examined prior and after radiotherapy treatment (RT) treatment. There have been previous studies on lipid profiles in PCa patients but with treatment methods other than RT (Ahn et al., 2009; Anand & Yusuf, 2011; Hayashi et al., 2012; Kitahara et al., 2011; Mondul, Clipp, Helzlouer, & Platz, 2010; Moses et al., 2009; Platz et al., 2009; Van Hemelrijck et al., 2011). The current study aimed to find connections between the factors such as age, cancer stage or treatment with regards to lipid profile. The examined hypothesis was that serum lipid levels could be potentially modifiable by RT and have some prognostic power.

Materials and Methods

Characteristics of Subjects

This is a retrospective study of 91 Caucasian men who were treated with external beam RT for PCa in Department of Radiotherapy of the Regional Clinical Hospital of Zielona Gora. This study was approved by the ethics committee at District Medical Council in Zielona Gora No 2/57/2012, and both oral and written consents were obtained from the subjects. The study was conducted by one physician over a period of 4 years between 2012 and 2016. The Eastern Cooperative Oncology Group (ECOG) scale was used and the subjects were classified according to the scale: 0–2. Blood samples were collected before RT (on the morning after fasting and before the initiation of androgen deprivation therapy [ADT]) and after the entire course of treatment in 3-month intervals for up to 4 years. The blood was evaluated with regards to lipid profile. The Roche Diagnostics GmbH Sandhofer Str.116 Mannheim Germany, Roche/Hitachi Cobas C Systems, and commercial kits were used to assess the lipid serum levels. The reference values for the normal ranges of the measured levels used by the Clinical Hospital of Zielona Gora are as follows: CHOL is 130–200 mg/dl, HDL are 35–80 mg/dl, LDL are 50–130 mg/dl, triglycerides (TG) are 65–150 mg/dl, and VLDL are 0–45 mg/dl. All subjects were clinically diagnosed with PCa and confirmed by a histopathological examination. The cases were placed into categories according to the TNM clinical stage (T–primary tumor site, N–regional lymph node, and M–metastatic spread) and divided into two groups of patients: Group 1—elderly subjects >69 years old and Group 2—subjects ≤69 years old. In Group 1, 40 men received treatment with radical prostate RT without nodal pelvis treatment, and 18 men received palliative RT (bone metastases RT without prostate RT). In Group 2, 21 men underwent radical prostate RT without nodal pelvis treatment, and 12 men had palliative RT (bone metastases RT without prostate RT). The 11 local regional subjects (48 patients ~52% of the total number of patients) and metastatic PCa patients (30 patients – 33% of the total) obtained ADT treatment with the exception of 13 patients with Gleason score of ≤6 and prostate specific antigen (PSA) <10 ng/ml. Ten in Group 1 and 13 in Group 2 with hardness disease (bone pain and bone metastases) received bisphosphonates—zoledronic acid (ZA)-intravenous infusion every 21 days with check parameters such as calcium and creatine concentration levels. During the anamnesis, all subjects were asked about the duration of any treatment with statins, diabetes, and alcohol and nicotine use. Subjects qualified for the study did not have any aggravating factor like diabetes and restrained from alcohol and nicotine use during the treatment. Subjects’ characteristics are summarized in Table 1.

Radiotherapy Treatment Used

Sixty subjects (those with metallic markers in the prostate gland) received radical RT treatment. The energy used over the course of treatment was as follows: a 6 MV and 15 MV photon beam for both intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) to the total dose of 76 Gy with 2 Gy per fraction, five consecutive days per week for the duration of 6–7 weeks; palliative subjects received 2D conformal...
radiotherapy (CRT) with a conventional fractionalization of 4–8 Gy with the total dose of 6–20 Gy.

### Statistical Analysis

This is a longitudinal study in which any changes of concentrations in the chosen biomarkers were examined for each participant over time—at 10 consecutive time points before and after RT treatment. Since a repeated measures' design was taken into account in this statistical analysis, a multilevel (hierarchical) modeling was applied. In particular, multilevel models are generalizations of linear models relying on nested random analysis of variance; they recognize the existence of data hierarchies by allowing for residual components at each level in the hierarchy (when a design includes both fixed and random effects, it is often called a mixed effects model). In the assumed concept, concentrations of the biomarkers with time and risk factors were analyzed using a stratified linear regression following a linear relation (concentration = time * risk factor), and the regression with an interaction term (concentration = time * risk factor; Raudenbush & Bryk, 2001). The following serum lipid concentrations (response variables) were modeled in the study: CHOL, HDL, LDL, VLDL, and TG. The selected available set of risk factors (explanatory variables) reported in Table 1 was used. In the analysis, only the statistically significant results of the stratified and interaction regression coefficients ($p < .05$) were considered. Results are reported in Table 2. Other relations of analyzed risk factors and lipid serum concentrations were statistically insignificant and were not presented in this article. Only one variable was considered significant in the statistical analysis and it concerned the patients’ age with the cut-off point = 69 years. Lipid serum concentrations in patients’ blood were measured before the RT treatment and after the completion of the whole course of treatment in up to eight consecutive follow-up visits every 3 months. The date gathered ranged from 100% to 3.3% completeness from first to eighth visit (from 17 to 1,837 days after treatment), with an average period between visits = 77 days. The statistical computation was performed in the MASS package (Package ‘MASS’, 2018) using the R platform (R Core Team, 2018).

### Results

In this study, the correlations between the lipid profiles and the age of the subject post RT treatment were checked. It is of note, however, that most of the results were statistically significant for interaction regression. It means that the concentrations of the selected biomarkers change over time after RT, except TG, which is stratified (see Table 2 for details). Taking all the subjects into account, the results are as follows: the CHOL level decreased over time after RT ($p = .0445$) together with an increase in PSA concentration ($p = .0366$). The CHOL reduction was slower over time in patients with a higher PSA compared to those with a lower PSA concentration ($p = .0059$). A faster decrease of HDL was observed over time with a higher concentration of PSA ($p = .0053$) and a higher Gleason score ($p = .0304$). Contrary to HDL results, the higher concentration level of PSA accompany to slowly decrease of LDL over time. The ECOG status correlation with LDL ($p = .0688$) and combined with the presence of ZA did not lead to any significant changes of LDL over time ($p = .0823$). The treatment without the use of statins resulted in the slight increase of LDL ($p = .0079$) but without statistical significance over time. The VLDL was only statistically significant after RT in correlation with the ECOG status (the VLDL decreased with the increase of ECOG status [$p = .0455$]). The study showed that TG decreased after RT only in Group 1 ($p = .0196$), but over time is statistically insignificant ($p = .3156$). Finally, HDL was

### Table 1. Patients’ Clinical Characteristics.

| Feature                        | Patients no 91 (100%) |
|--------------------------------|-----------------------|
| Age:                           | 72 (50–87)            |
| Median (range)                 | 50–69                 |
| 70–87                          | 36 (40)               |
| ECOG performance status:       | 20 (22)               |
| 0                              | 22 (25)               |
| 1                              | 31 (34)               |
| Histological diagnosis:        | 91 (100)              |
| Differentiation:               | 31 (34)               |
| Gleason score 2–6              | 24 (26)               |
| Gleason score 7                | 36 (40)               |
| Gleason score 8–10             | 20 (22)               |
| Statins use:                   | 78 (85)               |
| ADT use:                       | 41 (45)               |
| Radiotherapy:                  | 27 (30)               |
| Radical treatment total:       | 61 (67)               |
| Group 1: ≥69 years             | 40                    |
| Group 2: ≤69 years             | 21                    |
| Palliative treatment total:    | 30 (33)               |
| Group 1: ≥69 years             | 18                    |
| Group 2: ≤69 years             | 12                    |

Note. ECOG = Eastern Cooperative Oncology Group; PSA = prostate-specific antigen; ADT = androgen deprivation therapy.
Table 2. Multilevel Modeling of Biomarker Concentrations.

| Study group | Response variable | Regression coefficient (risk factor) | Mean | SE  | p value |
|-------------|-------------------|-------------------------------------|------|-----|---------|
| All patients| VLDL              | Intercept                           | 30   | 6.0 | <.0001  |
|             |                   | ECOG                                | 1.8  | 4.2 | .6669   |
|             |                   | Time                                | 0.0098 | 0.0067 | .1490   |
|             |                   | ECOG*Time                           | −0.0098 | 0.0048 | .0455   |
|             | HDL               | Intercept                           | 55   | 3.7 | <.0001  |
|             |                   | Gleason                             | −0.3642 | 1.5403 | .8136   |
|             |                   | Time                                | 0.0055 | 0.0046 | .2352   |
|             |                   | Gleason*Time                        | −0.0049 | 0.0022 | .0304   |
|             | CHOL              | Intercept                           | 198  | 5.0 | <.0001  |
|             |                   | PSA                                 | −0.0470 | 0.0222 | .0366   |
|             |                   | Time                                | −0.0156 | 0.0077 | .0445   |
|             |                   | PSA*Time                            | 0.00018 | 0.00007 | .0059   |
|             | HDL               | Intercept                           | 54   | 2.1 | <.0001  |
|             |                   | PSA                                 | 0.0065 | 0.0088 | .4593   |
|             |                   | Time                                | −0.0002 | 0.0025 | .9354   |
|             |                   | PSA*Time                            | −0.00006 | 0.00002 | .0053   |
|             | LDL               | Intercept                           | 115  | 4.5 | <.0001  |
|             |                   | PSA                                 | −0.0144 | 0.0195 | .4634   |
|             |                   | Time                                | −0.0093 | 0.0070 | .1864   |
|             |                   | PSA*Time                            | 0.00013 | 0.00006 | .0314   |
|             | TG                | Intercept                           | 177  | 16  | <.0001  |
|             |                   | Age > 69                            | −44  | 19  | .0196   |
|             |                   | Time                                | 0.0189 | 0.0188 | .3165   |
|             | HDL               | Intercept                           | 54   | 3.1 | <.0001  |
|             |                   | Age > 69                            | −0.1223 | 3.9946 | .9757   |
|             |                   | Time                                | −0.0102 | 0.0041 | .0140   |
|             |                   | Age > 69*Time                       | 0.0103 | 0.0049 | .0379   |
|             | LDL               | Intercept                           | 65   | 19  | .0008   |
|             |                   | Statins                             | 28   | 10  | .0079   |
|             |                   | Time                                | 0.0378 | 0.0279 | .1775   |
|             |                   | Statins*Time                        | −0.0239 | 0.0153 | .1213   |
| Radial      | TG                | Intercept                           | 206  | 23  | <.0001  |
|             |                   | Age > 69                            | −64.9 | 25.9  | .0151   |
|             |                   | Time                                | 0.020  | 0.026  | .4335   |
| Palliative  | HDL               | Intercept                           | 57   | 4.3 | <.0001  |
|             |                   | Age > 69                            | −8.5  | 5.7  | .1469   |
|             |                   | Time                                | −0.022  | 0.009  | .0159   |
|             |                   | Age > 69*Time                       | 0.026  | 0.010  | .0141   |

Note. ECOG = Eastern Cooperative Oncology Group; VLDL = very low density lipoproteins; LDL = low density lipoproteins; HDL = high density lipoproteins; CHOL = cholesterol; TG = triglycerides.

Discussion

After the radiation treatment, total CHOL and LDL among men with a more advanced disease (PSA, ECOG) decreased more slowly than among men with a less advanced disease. At the same time, HDL among those with a more advanced disease (PSA, Gleason score) decreased faster relative to those with a less aggressive disease. The treatment with the use of statins and ZA showed no significance with regards to lipid levels. After the radical RT treatment, the levels of TG in younger men was reduced with time ($p = .0140$); however, the decrease in the older group is smaller than in the younger group ($p = .0379$). With the division of the subjects into two groups according to their palliative and/or radical procedures, the concentrations of other lipids showed no statistically significant results. In all subjects, the HDL decreased after RT ($p = .0159$) but in the older palliative group, the HDL decrease happened at a slower pace ($p = .0141$). The only changes noticed after radical treatment were in the concentrations of TG (in Group 1, TG decreased after therapy [$p = .0151$]).
higher than among the older ones and did not change over time. After the palliative RT in the older patients, HDL decreased faster. Moon et al. (2015) presented a thesis that a high level of CHOL increases the size of the tumor. This study shows that the CHOL decreases after RT but its reduction is slower in patients with a higher PSA compared to those with a lower PSA. This correlation is reversed between PSA and HDL levels—the decrease of HDL is faster in patients with a higher concentration of PSA and a higher Gleason score. Among the elderly men (>69 years), decrease of HDL is slower after treatment than in the group ≤69 years. Decrease of lipid levels in both groups is most likely due to the radiation. The metastases and advancement of diseases correlate with angiogenesis (a cancer growth and metastasis factor). In the studies of Raju et al. (2014) on cervical cancer and Ghahremanfard, Mirmohammadkhani, Shahnazari, Gholami, and Mehdizadeh (2015) on breast, colon, gastric, and ovarian cancers, it was observed that a statistically significant increase of CHOL and LDL values correlates with the advancement of the diseases. LDL is one of many factors that take part in the process of angiogenesis, which can inhibit this process. The growth of tumor and metastasis can be stopped by inhibiting angiogenesis (Vedavyas, 2013). In this study, decrease of LDL after treatment was shown and it was observed to be slower in higher concentration PSA and ECOG performance status. A borderline level decrease of LDL after RT was noticed when the treatment was combined with the use of bisphosphonates like ZA to reduce skeletal-related events (bone metastases). In literature, ZA has previously been shown to reduce levels of LDL (Gonnelli et al., 2014). This borderline result could be due to the small size of the subgroup treated with ZA. The role of statins as a preventative measure in the development of PCa as the factor which lowers CHOL levels is controversial. There are studies which report that statins inhibit the progression of cancer (Farwell et al., 2008; Morote et al., 2014; Pelton, Freeman, & Solomon, 2012; Solomon & Freeman, 2008; Wolny-Rokicka, Tukiendorf, Wydmański, & Zembroń-Lacny, 2017). In this study, the treatment without statins resulted in the increase of LDL but without statistical significance over time. PCa patients often display significantly lower levels of serum cholesterol (Bielecka-Dąbrowa, Hannam, Rysz, & Banach, 2011; Munir et al., 2014) but it is questionable whether these factors may be used to predict the risk of cancer. In the study by Allott et al. (2014), elevated serum TG levels were associated with an increased risk of PCa recurrence. In Hayashi et al.’s (2012) study, the authors emphasized the same trend of increased TG levels together with a higher Gleason score ≥8 in elderly patients as a factor in PCa recurrence. In the current study, RT was a chosen method of treatment and proved to show a statistically significant association between TG level decrease of LDL after treatment was noticed when the treatment was combined with the use of bisphosphonates like ZA to reduce skeletal-related events (bone metastases). This study described changes in blood lipid profiles among middle-aged and elderly men with PCa after RT. Changes in lipid levels are differentially affected by various other factors such as somatic disease—neurological, cardiac, and gastrointestinal somatic symptoms. This study only examines the clinical correlation between RT and its effect on the lipid profile in elderly patients. In order to properly evaluate this “effect,” a broader group of subjects would be needed with the adjustment for confounding factors including ADT, ZA, statins, type of RT, disease severity, diabetes, BMI, and so forth. It was observed that RT treatment could lead to a decrease in lipid serum concentration. A broader study could further prove this.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Edyta Wolny-Rokicka https://orcid.org/0000-0002-9592-6433
Agnieszka Zembroń-Lacny https://orcid.org/0000-0001-7596-9850

References

Ahn, J., Lim, U., Weinstein, S. J., Schatzkin, A., Hayes, R. B., Virtamo, J., & Albanes, D. (2009). Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiology, Biomarkers & Prevention, 18(11), 2814–2821.
Allott, E. H., Howard, L. E., Cooperberg, M. R., Kane, C. J., Aronson, W. J., Terris, M. K., … Freedland, S. J. (2014). Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiology, Biomarkers & Prevention, 23(11), 2349–2356.
Anand, S. S., & Yusuf, S. (2011). Stemming the global tsunami of cardiovascular disease. The Lancet, 377(9765), 529–532.
Anum, E. A., & Adera, T. (2004). Hypercholesterolemia and coronary heart disease in elderly: A meta-analysis. Annals of Epidemiology, 14(9), 705–721.
Bielecka-Dąbrowa, A., Hannam, S., Rysz, J., & Banach, M. (2011). Malignancy-associated dyslipidemia. The Open Cardiovascular Medicine Journal, 5, 35–40.

Farwell, W. R., Scranton, R. E., Lawler, E. V., Lew, R. A., Brophy, M. T., Fiore, L. D., & Gazzano, J. M. (2008). The association between statins and cancer incidence in veterans population. Journal of the National Cancer Institute, 100(2), 134–139.

Ghahremanfard, F., Mirmohammadkhani, M., Shahnazari, B., Gholami, G., & Mehdizadeh, E. J. (2015). The valuable role of measuring serum lipid profile in cancer progression. Oman Medical Journal, 3(5), 353–357.

Gonnelli, S., Caffarelli, C., Tanzilli, L., Pondrelli, C., Lucani, B., Franci, B. M., & Nuti, R. (2014). Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone, 61, 27–32.

Hashmi, S., Wang, Y., Suman, D. S., Parhar, R. S., Collison, K., Conca, W., . . . Gaugler, R. (2015). Human cancer: Is it linked to dysfunctional lipid metabolism? Biochimica et Biophysica Acta (BBA) – General Subjects, 1850(2), 352–364.

Hayashi, N., Matsushima, M., Yamamoto, T., Sasaki, H., Takahashi, H., & Egawa, S. (2012). The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years. BJU International, 109(4), 515–519.

Huang, C., & Freter, C. (2015). Lipid metabolism, apoptosis and cancer therapy. International Journal of Molecular Sciences, 16, 924–949.

Jowett, M. (1931). The phosphatide and cholesterol contents of normal and malignant human tissues. Biochemical Journal, 25(6), 1991–1998.

Kitahara, C. M., Berrington de González, A., Freedman, N. D., Huxley, R., Mok, Y., Jee, S. H., & Samet, J. M. (2011). Total cholesterol and cancer risk in a large prospective study in Korea. Journal of Clinical Oncology, 29(12), 1592–1598.

Mondul, A. M., Clipp, S. L., Helzlsouer, K. J., & Platz, E. A. (2010). Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes & Control, 21(1), 61–68.

Moon, H., Ruelcke, J. E., Choi, E., Sharpe, L. J., Nassar, Z. D., Bielefeldt-Ohmann, H., . . . Hill, M. M. (2015). Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1. Oncotarget, 6(10), 7438–7453.

Morote, J., Celma, A., Planas, J., Placer, J., de Torres, I., Olivan, M., & . . . Doll, A. (2014). Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness. International Journal of Molecular Sciences, 15(8), 13615–13623.

Moses, K. A., Abd, T. T., Goodman, M., Hsiao, W., Hall, J. A., Marshall, F. F., . . . Issa, M. M. (2009). Increased low density lipoprotein and increased likelihood of positive prostate biopsy in Black Americans. Journal of Urology, 182(5), 2219–2225.

Munir, R., Usman, H., Hasnain, S., Smans, K., Kalbacher, H., & Zaïdi, N. (2014). Atypical plasma lipid profile in cancer patients: Cause or consequence? Biochimie, 102, 9–18.

Murai, T. (2015). Cholesterol lowering: Role in cancer prevention and treatment. Biological Chemistry, 396(1), 1–11.

Pelton, K., Freeman, M. R., & Solomon, K. R. (2012). Cholesterol and prostate cancer. Current Opinion in Pharmacology, 12(6), 751–759.

Platz, E. A., Till, C., Goodman, P. J., Parnes, H. L., Figg, W. D., Albanes, D., . . . Cristal, A. R. (2009). Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiology, Biomarkers & Prevention, 18(11), 2807–2813.

Raju, K., Punnayanapalya, S. S., Marityappa, N., Eshwarappa, S. M., Anjaneya, C., & Kai, L. J. (2014). Significance of the plasma lipid profile in cases of carcinoma of cervix: A tertiary hospital based study. Asian Pacific Journal of Cancer Prevention, 15(8), 3779–3784.

Raudenbush, S. W., & Bryk, A. S. (2001). Hierarchical linear models: Applications and data analysis methods (2nd ed.). Thousand Oaks, CA: Sage Publications.

Riedel, S., Abel, S., Swanevelder, S., & Gelderblom, W. C. A. (2015). Induction of an altered lipid phenotype by two cancer promoting treatments in rat liver. Food and Chemical Toxicology, 78, 96–104.

Rodriguez, C., Raposo, B., Martinez-González, J., Casani, L., & Badimon, L. (2002). Low density lipoproteins down-regulate lysyl oxidase in vascular endothelial cells and the arterial wall. Arteriosclerosis, Thrombosis and Vascular Biology, 22(9), 1409–1414.

Solomon, K. R., & Freeman, M. R. (2008). Do the cholesterol-lowering properties of statins affect cancer risk? Trends in Endocrinology & Metabolism, 19(4), 113–121.

R Core Team. (2018). R: Version 3.5.1. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Retrieved from https://www.r-project.org/

Van Hemelrijck, M., Garmo, H., Holmberg, L., Walldius, G., Jungner, I., Hammar, N., & Lambe, M. (2011). Prostate cancer risk in the Swedish AMORIS study: The interplay among triglycerides, total cholesterol, and glucose. Cancer, 117(10), 2086–2095.

Vedavayas, S. (2013). Effect of low density lipoprotein on cancer metastasis. Online Journal of BioSciences and Informatics, 4(2), 207.

White, C. P. (1909). On the occurrence of crystals in tumours. The Journal of Pathology and Bacteriology, 13(1), 3–10.

Wolny-Rokicka, E. I., Tukiendorf, A., Wydmański, J., . . . Zembroń-Łacny, A. (2017). The comparison and estimation of the prognostic value of lipid profiles in patients with prostate cancer depends on cancer stage advancement. American Journal of Men’s Health, 11(6), 1745–1751.

Yasuda, M., & Bloor, W. R. (1932). Lipid content of tumors. Journal of Clinical Investigation, 11(4), 677–682.